Browse the evidence

Obesity is a major risk factor for various cancers, including endometrial, ovarian, prostate, colorectal, pancreatic, liver, gallbladder, kidney, thyroid, and meningioma, as well as hematological malignancies like multiple myeloma and leukemia.

Maintaining a healthy weight reduces your risk of developing several types of cancer, including colorectal, kidney, and endometrial cancer. Weight management through lifestyle changes is a key preventive strategy.

Obesity is a significant risk factor for respiratory diseases, including obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), and asthma, primarily due to mechanical effects on lung volume and airway collapse.

If you have obesity, you are at higher risk for sleep apnea and breathing problems. Excess weight can narrow your airways and reduce lung capacity. Losing weight can help improve breathing and reduce the severity of conditions like asthma and sleep apnea.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide reduce body weight primarily by suppressing energy intake through activation of GLP-1 receptors in the central nervous system (CNS) and peripheral vagal afferent pathways, rather than by increasing energy expenditure.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, primarily by reducing appetite and food intake through brain and gut signaling. They are taken once weekly. While they achieve significant weight loss (15-20%+ in trials), real-world results vary, and about a third of users may not lose enough weight to be clinically effective. Common side effects like nausea are frequent but often manageable with dose titration. These drugs are not a magic bullet for everyone, especially those with type 2 diabetes or lower starting weights, and require medical supervision.

Structured endurance or resistance exercise training induces distinct, comprehensive molecular adaptations across multiple organ systems, serving as the mechanistic basis for health benefits.

This paper establishes that endurance and resistance exercises trigger different molecular pathways. To maximize health benefits, you should incorporate both types of exercise, as they affect different molecular transducers in your muscles, fat, and blood. The specific molecular details are still being mapped, but the structural commitment (12 weeks) is key to seeing these changes.

Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.

Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.

GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.

If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.

Gastrointestinal adverse events (nausea, vomiting, diarrhea) associated with once-weekly semaglutide 2.4 mg are transient, mild-to-moderate, and contribute negligibly (<1 percentage point) to the total weight loss achieved.

If you are prescribed once-weekly semaglutide 2.4 mg, expect gastrointestinal side effects like nausea or diarrhea, especially when starting or increasing the dose. These symptoms are typically mild, temporary, and resolve on their own. Crucially, do not assume these side effects are necessary for the drug to work; the medication causes weight loss primarily by regulating appetite and satiety, not by making you sick. Most patients tolerate the medication well enough to stay on the full dose.

Increasing cardiorespiratory fitness (CRF) or physical activity (PA) consistently reduces all-cause and cardiovascular mortality risk, whereas intentional weight loss does not consistently reduce mortality risk and may increase it in healthy individuals.

Prioritize increasing your physical activity and cardiorespiratory fitness over focusing on weight loss. Regular exercise provides consistent mortality benefits that are independent of whether you lose weight. If you are overweight or obese, becoming 'fit' significantly lowers your health risks, often more effectively than trying to lose weight alone.

Visceral adipose tissue accumulation is a primary risk factor for cardiometabolic disease, whereas subcutaneous fat is metabolically neutral or healthy.

Not all fat is created equal. Visceral fat (around your organs) is dangerous and increases your risk of diabetes and heart disease. Subcutaneous fat (under your skin) is less harmful. Focus on reducing visceral fat through diet and exercise, as this has the biggest impact on your metabolic health.

A 10-year intensive lifestyle intervention (caloric restriction and increased physical activity) significantly delays the onset of moderate or severe physical disability and increases disability-free life expectancy in adults with type 2 diabetes, particularly in women and those without cardiovascular disease.

If you have type 2 diabetes, committing to a structured lifestyle program involving calorie-controlled eating and regular physical activity (aiming for ~175 minutes of moderate activity per week) can significantly delay the onset of physical disability. This benefit is particularly pronounced for women and those without existing heart disease. While it may not extend your total lifespan, it can add nearly a year to your life spent free from physical limitations, improving your quality of life in your later years.

GLP-1 receptor agonists (GLP-1RAs) reduce body weight primarily by suppressing food intake through central nervous system mechanisms, including hypothalamic and hindbrain signaling and vagal afferent stimulation.

GLP-1 medications like semaglutide and liraglutide help you lose weight by signaling your brain to feel full and eat less, rather than by burning more calories. This effect is driven by the drug acting on satiety centers in the brain and vagus nerve. While side effects like nausea are common initially, they often subside over time. Consistent use is required to maintain weight loss, as stopping the medication typically leads to weight regain.

GLP-1 receptor agonists reduce cardiovascular risk (MACE) and improve renal outcomes in patients with Type 2 Diabetes, independent of weight loss.

For patients with Type 2 Diabetes, especially those with heart disease or kidney risks, GLP-1 medications offer significant protection against heart attacks, strokes, and kidney failure. These benefits are independent of weight loss and are supported by extensive clinical trial data. The choice between daily injections, weekly injections, or oral tablets depends on patient preference and tolerance.

Bariatric surgery (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) is an effective treatment for obesity and T2DM, capable of inducing remission of diabetes through both weight-loss-dependent and weight-loss-independent mechanisms.

Bariatric surgery is a powerful tool for treating obesity and Type 2 Diabetes. It can lead to diabetes remission (normal blood sugar without meds) through both weight loss and hormonal changes. It is invasive and carries risks like nutrient deficiencies, so it requires lifelong medical monitoring.

Metformin provides modest weight loss (average ~2.1 kg/year) and improves insulin sensitivity, making it a first-line treatment for T2DM, though it is not FDA-approved specifically for weight loss.

Metformin is a standard first-line medication for Type 2 Diabetes. It helps control blood sugar and may lead to modest weight loss (about 2 kg per year), but it is not a powerful weight-loss drug. It is generally safe and well-tolerated, though some people experience gastrointestinal side effects.

The physical function benefits of long-term intensive lifestyle intervention are more pronounced in older adults (≥60 years) compared to younger adults (<60 years).

If you are over 60, the mobility benefits of lifestyle changes may be even more valuable to you than for younger people, as the intervention had a larger effect on physical function scores in this age group.

GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.

If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.

If you have chronic kidney disease and are overweight or obese, ask your doctor about GLP-1 receptor agonists like semaglutide or liraglutide. These medications are not just for weight loss; they have been proven to protect your heart and kidneys, even if you do not have diabetes. They are available in both daily and weekly formulations, and sometimes orally, making them a versatile option for managing your overall metabolic health.

Liraglutide 1.8 mg/day reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality in patients with Type 2 Diabetes and high cardiovascular risk.

If you have Type 2 Diabetes and are at high risk for heart problems, adding a daily 1.8 mg liraglutide injection can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes, without increasing the risk of heart failure hospitalization.

Semaglutide (2.4 mg weekly) produces a clinically significant reduction in systolic blood pressure (approx. 4.8 mmHg) and diastolic blood pressure (approx. 2.5 mmHg) in adults with obesity but without diabetes, even among those with normotensive baseline blood pressure.

If you have obesity and high blood pressure (or even normal blood pressure), semaglutide 2.4 mg taken once weekly can significantly lower your blood pressure. This benefit exists even if you are not currently diagnosed with hypertension. It is a weight-centric approach to managing blood pressure.

Insulin therapy is associated with significant weight gain (mean 4.3 kg) in patients with Type 2 Diabetes, driven by caloric conservation, anabolic effects, and defensive eating to avoid hypoglycemia.

If you are on insulin and gaining weight, know that this is a known side effect caused by how insulin stores energy and your body's response to prevent low blood sugar. Discuss switching to or adding GLP-1 agonists with your doctor, as they can help with weight loss while managing blood sugar.

A 12-week treatment with dulaglutide prevents post-cessation weight gain in the short term (12 weeks), but this benefit is lost after discontinuation, resulting in similar weight gain to placebo at 52 weeks.

Dulaglutide can help you avoid gaining weight during your first 12 weeks of quitting smoking. However, once you stop the injections, you will likely gain weight similar to someone not taking the drug. To maintain weight loss, you may need to stay on the medication longer than 12 weeks.

Interval training (IT) and moderate intensity continuous training (MICT) produce equivalent changes in whole-body fat mass and fat-free mass over time.

If your goal is to change your body composition (lose fat or gain muscle), it does not matter whether you choose high-intensity interval training (HIIT) or moderate-intensity continuous training (MICT). Both approaches yield similar results. Focus on choosing the type of exercise you enjoy and can stick with consistently, as adherence is likely more important than the specific intensity profile for long-term body composition changes.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), including cardiovascular mortality, myocardial infarction, and stroke, in patients with type 2 diabetes and high cardiovascular risk.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like Semaglutide or Liraglutide) are proven to lower your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of weight loss in some cases, though weight loss often accompanies it. Discuss these options with your doctor, especially if you are at high risk.